Metonitazene

Metonitazene is an analgesic drug related to etonitazene, which was first reported in 1957,[1] and has been shown to have approximately 100 times the potency of morphine by central routes of administration,[2], but if used orally it has been shown to have approximately 10 times the potency of morphine[3].

Metonitazene
Identifiers
CAS Number
PubChem CID
Chemical and physical data
FormulaC21H26N4O3
Molar mass382.464 g·mol−1
3D model (JSmol)

Its effects are similar to other opioids like fentanyl and heroin, including analgesia, euphoria, sleepiness[3]. Adverse effects include vomiting, and respiratory depression that can potentially be fatal. Because of high dependency potential and dangerous adverse effects it has never been introduced in pharmacotherapy.


See also

References
  1. Hunger, A.; Kebrle, J.; Rossi, A.; Hoffmann, K. (1957-10-15). "[Synthesis of analgesically active benzimidazole derivatives with basic substitutions]". Experientia. 13 (10): 400–401. doi:10.1007/bf02161116. ISSN 0014-4754. PMID 13473817.
  2. Hunger, A.; Kebrle, J.; Rossi, A.; Hoffmann, K. (1960). "Benzimidazol-Derivate und verwandte Heterocyclen III. Synthese von 1-Aminoalkyl-2-nenzyl-nitro-benzimidazolen". Helvetica Chimica Acta. 43 (4): 1032–1046. doi:10.1002/hlca.19600430412. ISSN 0018-019X.
  3. Bromig, G. (1958-10-15). "[New powerful analgetics and their clinical testing]". Klinische Wochenschrift. 36 (20): 960–963. doi:10.1007/bf01486702. ISSN 0023-2173. PMID 13612082.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.